Global Medical Launch Lead, Gynaecological Oncology - Full-time - UK, remote position with travel as needed.

Portfolio Focus

Oncology and oncology supportive care, including priority pre-launch, launch and post-launch assets

About Pharmanovia

Pharmanovia is a dynamic, fast-growing international pharmaceutical company with a portfolio of over 20 brands across more than 160 markets. Our mission is to improve patient health globally by revitalising niche, tried-and-trusted medicines. Since its inception in 2013, Pharmanovia has grown consistently year on year, focusing on delivering high-quality branded prescription medicines to patients, prescribers and healthcare providers worldwide. Our people are at the heart of our business, with more than 300 employees representing 29 nationalities across our international offices. We are an agile, committed and innovative global speciality pharma business and a preferred partner for innovator pharma companies, helping to transform the lifecycle management of iconic medicines. Our therapeutic areas include Cardiovascular, Oncology, Endocrinology and Neurology.

About the Role

We are seeking an experienced Global Medical Launch Lead - Gynaecological Oncology to expand our growing business. Reporting to the Global Head of Medical Affairs, the Global Medical Launch Lead owns the global medical strategy and launch readiness for Pharmanovia's priority gynaecological-oncology launch assets and co-owns the integrated cross-functional launch plan with the commercial lead for each asset. The initial focus is ovarian cancer and women's cancers. The role translates clinical evidence into a differentiated medical position and scientifically robust input to the access case, supporting appropriate clinical decision-making across markets. It owns the scientific narrative and the asset's evidence priorities, and partners with the Global RWE function on the evidence, congress and publication plans. It leads the medical contribution to HTA and payer engagement, global KOL and scientific society engagement, and the coordination of medical launch readiness with priority markets and cross-functional partners. This is a strategic and highly hands-on global role, delivered through influence rather than direct line management. It establishes a single medical strategy and evidence narrative for the asset across Pharmanovia's licensed territories, deploys it first in the priority European launch markets, and extends it to other markets, including those led by General Managers or partners, as they approach launch. In a lean, fast-moving speciality pharma environment, the role holder must move fluidly from setting global medical strategy to personally leading priority KOL engagement and HTA work, advisory boards and the practical problem-solving that launches require, while maintaining independent medical judgement and the non-promotional character of Medical Affairs.

Responsibilities

• Own the global medical strategy, positioning and evidence narrative for the priority launch asset(s) in ovarian cancer and women's cancers.
• Build a differentiated, evidence-based position from the pivotal data, defining the target scientific claims and the medical input for positioning relative to relevant standards of care.
• Define and codify the medical launch approach for gynaecological oncology, and contribute it to Pharmanovia's shared launch playbook for reuse across the oncology portfolio.
• Define the asset's evidence priorities and co-develop the post-authorisation evidence plan (real-world evidence, registries, investigator-initiated research and phase IV or other studies) with the Global RWE function, which leads its design, governance and execution.
• Prioritise the evidence that strengthens the generalisability of the pivotal data to European clinical practice and supports HTA and appropriate clinical use.
• Own the medical response to clinically relevant co-medication and drug-interaction considerations, including prescriber education and defining any supporting evidence needs.
• Partner with Clinical Development on protocol and endpoint input, feasibility, investigator and site identification and the communication of approved results.
• In close collaboration with Market Access/HEOR, lead the global medical contribution to the access strategy and value narrative for the launch asset(s), ensuring the clinical value proposition and payer evidence are scientifically robust and patient-relevant.
• Support country HTA and payer engagement (for example, G-BA, HAS, NICE, SMC and other national processes) with comparator strategy, relative-effectiveness evidence, submission input, clarification responses and expert preparation, in line with agreed cross-functional roles.
• Identify reimbursement-relevant evidence gaps and co-develop the real-world evidence, epidemiology, outcomes and comparative-effectiveness plans to address them, without assuming ownership of pricing or commercial negotiations.
• Provide medical input to labelling, the target product profile, safety communication and clinically relevant interaction messaging, in partnership with Regulatory Affairs and Pharmacovigilance.
• Ensure the scientific narrative and launch materials remain consistent with the approved label and evidence.
• Build and own the global KOL map in gynaecological oncology and women's cancers, design and run global advisory boards, and support priority-market advisory boards led by the country medical teams.
• Develop trusted peer-to-peer relationships with leading clinicians, investigators, scientific societies (for example ESMO and ESGO) and patient organisations, and personally lead priority global engagements.
• Ensure external insights are captured, synthesised and translated into visible decisions on strategy, evidence, access and launch execution.
• Shape the congress (including ESMO and ESGO), publication, and scientific communications plan for the launch asset(s) with the Global RWE function, which owns it, ensuring it reflects the scientific narrative and launch priorities.
• Define the scientific narrative and core evidence platform in partnership with Regulatory, Market Access, and Commercial, ensuring accuracy, balance, and appropriate localisation.
• Oversee needs-based scientific education for external stakeholders and internal launch teams, including country MSLs.
• Ensure all activities comply with applicable laws, industry codes, company policies, pharmacovigilance requirements, quality standards, and Medical Affairs procedures, while preserving the non-promotional character of scientific exchange.
• Ensure unsolicited scientific questions are routed through Medical Information and that adverse events and product complaints identified by Medical Affairs are reported promptly.
• Manage the medical launch budget for the asset(s) (external engagement, advisory boards, and launch-readiness activities) as allocated through the asset governance, in coordination with the evidence, scientific communications, and country medical budgets, with disciplined prioritisation and transparent reporting.
• On request from Global Medical Affairs or Corporate Development, contribute medical input to the assessment of adjacent or pipeline opportunities; this is an occasional contribution rather than a core accountability.